临床数据全球首发专场

返回主日程
14:00 - 15:40
  • 主持人 Moderator
  • 陈力, 中国药促会研发专委会主委，华领医药CEO
  • CHEN Li, CEO, Hua Medicine (Shanghai) Ltd.
14:00 - 14:20
  • 项目 1
  • Project 1
  • 从减重到代谢重塑——依苏帕格鲁肽α超长效GLP-1 RA驱动的肥胖及相关代谢疾病创新治疗项目
  • Beyond Weight Loss to Metabolic Remodeling: Innovative Treatment of Obesity and Related Metabolic Diseases with Efsubaglutide Alfa, an Ultra-Long-Acting GLP-1 RA
  • 王庆华, 中国药促会研发专委会副主委，银诺医药创始人、董事长兼CEO，复旦大学特聘教授
  • WANG Qinghua, Founder, Chairman and CEO of Innogen Pharmaceuticals，Distinguished Professor at Fudan University
14:20 - 14:40
  • 项目 2
  • Project 2
  • 可穿戴感应式肿瘤电场治疗复发性胶质母细胞瘤【昆仑智鼎（北京）医疗技术有限公司】
  • Wearable Induced Tumor Treating Fields for Recurrent GBM Therapy (Kunlun Zhiding (Beijing) Medical Technology Co., Ltd.)
  • 康庄, 首都医科大学附属北京天坛医院神经外科临床试验PI
  • KANG Zhuang, Clinical Trial Principal Investigator, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University
14:40 - 15:00
  • 项目 3
  • Project 3
  • 靶向GPR84的免疫性疾病创新解决方案
  • Innovative Solutions for Immune Mediated Diseases Targeting GPR84
  • 侯永泰, 博骥源（上海）生物医药有限公司合伙创始人&CEO
  • HOU Yongtai, Co-founder & CEO, Burgeon Therapeutics Co., Ltd.
15:00 - 15:20
  • 项目 4
  • Project 4
  • CS32582治疗中重度斑块状银屑病：一项随机、双盲、安慰剂对照的Ib期临床试验
  • CS32582 for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Phase Ib Clinical Trial
  • 王欣昊, 深圳微芯生物科技股份有限公司研发中心副总裁
  • WANG Xinhao, Vice President, R&D Center, Shenzhen Chipscreen Biosciences Co., Ltd.
15:20 - 15:40
  • 项目 5
  • Project 5
  • TQB2102：HER2双表位ADC的破局之路
  • TQB2102: The Breakthrough Path of a HER2 Biparatopic ADC
  • 汪华媛, 正大天晴药业集团股份有限公司医学总监、胸部肿瘤医学负责人
  • WANG Huayuan, Medical Director and Head of Thoracic Oncology, Clinical Development, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.